Influenza vaccine for chronic obstructive pulmonary disease (COPD)

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 6, 2018, Pages

  Kopsaftis, Zoe ^a,b   Wood Baker, Richard ^c   Poole, Phillippa ^d  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; LIVE VACCINE;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUSTRY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MORTALITY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING; SYSTEMATIC REVIEW; THAILAND; UNITED KINGDOM; UNITED STATES; AGED; COMPLICATION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; DISEASE PROGRESSION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG DISEASES, OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 85049070502     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002733.pub3     Document Type: Review

References (66)

1. Cate TR, Kasel JA, Couch RB, Six HR, Knight V. Clinical trials of bivalent influenza/A/New Jersey/76-A/Victoria/75 vaccines in the elderly. Journal of Infectious Diseases 1977;136(Suppl):S518-25. 3206850
2. Fell PJ, O'Donnell HF, Watson NP, Simmins RL, Hasell SK. Longer term effects of live influenza vaccine in patients with chronic pulmonary disease. Lancet 1977;1(8025):1282-4. 3206852
3. Gorse GJ, Campbell MJ, Otto EE, Powers DC, Chambers GW, Newman FK. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically elderly with live attenuated or inactivated influenza virus vaccine. Journal of Infectious Diseases 1995;172:1-10. 3206854
4. Gorse GJ, Otto EE, Daughaday CC, Newman FK, Eickhoff CS, Powers DC, et al. Influenza virus vaccination of patients with chronic lung disease. Chest 1997;112(5):1221-33. 3206856
5. Gorse GJ, O'Connor TZ, Young SL, Habib MP, Wittes J, Neuzil KM, et al. Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest 2006;130:1109-16. 8759442
6. Gorse GJ, O'Connor TZ, Young SL, Mendelman PM, Bradley SF, Nichol KL, et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease : a VA cooperative study. Vaccine 2003;21:2133-44. 3206858
7. Neuzil KM, O'Connor TZ, Gorse GJ, Nichol KL. Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine. Clinical Infectious Diseases 2003;36(2):169-74. 8759443
8. Govaert ME, Dinant GJ, Aretz K, Masurel N, Sprenger MJW, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people:randomised double blind placebo controlled trial. BMJ 1993;307:988-90. 8759445
9. Govaert ME, Thijs CT, Masurel N, Sprenger JW, Dinant GJ, Knottnerus JA. The efficacy of Inflenza vaccination in elderly individuals-a randomised double-blind placebo controlled trial. JAMA 1994;272(21):1661-5. 8759446
10. Howells CHL, Tyler LE. Prophylactic use of influenza vaccine in patients with chronic bronchitis. A pilot trial. Lancet 1961;2:1428-32. 3206866
11. [no authors listed]. A study of live influenza virus vaccine in patients with chronic bronchitis. Report to Medical Research Council's committee on influenza and other respiratory virus vaccines. Advisory Group on Pulmonary Function Tests in Relation to Live Influenza Virus Vaccines. British Journal of Diseases of the Chest 1980;74(2):121-7. 3206868
12. Treanor JJ, Mattison HR, Dumyati G, Yinnon A, Erb S, O'Brien D, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Annals of Internal Medicine 1992;117:625-33. 3206872
13. Treanor J, Dumyati G, O'Brien D, Riley M, Riley G, Erb S, et al. Evaluation of cold-adapted, reassortant influenza B virus vaccines in elderly and chronically ill adults. Journal of Infectious Diseases 1994;169:402-7. 3206874
14. Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. Journal of the Medical Association of Thailand 2003;86(6):497-508. 8759448
15. Wongsurakiat P, Maranetra KN, Gulprasutdilog P, Aksornint M, Srilum W, Ruengjam C, et al. Adverse effects associated with influenza vaccination in patients with COPD:a randomized controlled study. Respirology 2004;9:550-6. 8759449
16. Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004;125:2011-20. 8759450
17. Ambrosch F, Konigstein RP, Olbrich E, Potschka W, Wiedermann G. Influenza immunisation, clinical results and serological tests [Klinische und serologische Untersuchungen zur Wirkung der Influenzaimpfung]. Aktuelle Gerontologie 1979;9:399-404. 3206882
18. Centanni S, Pregliasco F, Bonfatti C, Mensi C, Tarsia P, Guarnieri R, et al. Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease. Journal of Chemotherapy 1997;9(4):273-8. 3206884
19. Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults, and healthy volunteers. International Journal of STD and AIDS 1997;8:776-9. 3206886
20. Gorse GJ, Belse RB, Munn NJ. Safety of serum and antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases. Journal of Clinical Microbiology 1986;24(3):336-42. 3206888
21. Gorse GJ, Belshe RB, Munn NJ. Local and systemic antibody response in high-risk adults given live-attenuated and inactivated A virus vaccines. Journal of Clinical Microbiology 1988;26(5):911-8. 3206890
22. Gorse GJ, Belshe RB, Munn NJ. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest 1991;100(4):977-84. 3206892
23. Gorse GJ, Otto EE, Powers DC, Chambers GW, Eickhoff CS, Newman FK. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. Journal of Infectious Diseases 1996;173:285-90. 3206894
24. Howells CHL, Vesselinova-Jenkins CK, Evans AD, James J. Influenza vaccination and mortality from bronchopneumonia in the elderly. Lancet 1975;1(7903):381-3. 3206896
25. Keitel WA, Couch RB, Quarles JM, Cate TR, Baxter B, Maassab HF. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. Journal of Infectious Diseases 1993;167:305-11. 3206898
26. Lama A, Tatliei G, Aydin Tosun G, Yildirim N. Preventive effect of influenza vaccine on chronic obstructive pulmonary disease and bronchial asthma. Proceedings of the 1st World Congress on Vaccines and Immunization; 1998 April 26-30; Istanbul. 1998. 3206900
27. Margolis KL, Poland GA, Nichol KL, MacPherson DS, Meyer JD, Kron JE, et al. Frequency of adverse reactions after influenza vaccination. American Journal of Medicine 1990;88:27-30. 3206902
28. Medical Research Council (MRC). Field trial of influenza virus vaccine in patients with chronic bronchitis during the winter 1957-8. BMJ 1959;2:905-8. 3206904
29. Medical Research Council (MRC). Trials of live attenuated influenza virus vaccine in patients with chronic airways disease. British Journal of Diseases of the Chest 1984;78:236-47. 3206906
30. Paul WS, Cowan J, Jackson GG. Acute respiratory illness among immunised and non-immunised patients with high-risk factors during a split season of influenza A and B. Journal of Infectious Diseases 1988;157(4):633-9. 3206908
31. Mancini DA, Mendonça RM, Mendonça RZ, do Prado JA, Andrade Cde M. Immune response to vaccine against influenza in smokers, non-smokers and in individuals holding respiratory complications. Bollettino Chimico Farmaceutico 1998;137(1):21-5. 3206910
32. Powers DC, Fries LF, Murphy BR, Thumar B, Clements ML. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. Journal of Clinical Microbiology 1991;29(3):498-505. 3206912
33. Prevost JM, Vereerstraeten-Schmerber J, Lamy F, De Koster JP. Live attenuated influenza virus vaccines in patients with chronic broncho-pulmonary diseases. Scandinavian Journal of Respiratory Diseases 1975;56:58-69. 3206914
34. Saah AJ, Neufeld R, Rodstein M, La Montagne JR, Blackwelder WC, Gross P. Influenza vaccine and pneumonia mortality in a nursing home population. Archives of Internal Medicine 1986;146(12):2353-7. 3206916
35. Treanor JJ, Betts RF. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine 1998;16(18):1756-60. 3206918
36. Winson IG, Smit JM, Potter CW, Howard P. Studies with live attenuated influenza virus in chronic bronchitis. Thorax 1977;32:726-8. 3206920
37. Advisory Committee on Immunization Practises (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 1999;48(RR-4):1-28.
38. ATS 1995. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1995;152((5 Pt 2)):Suppl: S77-120.
39. American Thoracic Society (ATS)/European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD version 1.2. www.thoracic.org/copd-guidelines/ (accessed 5 May 2016).
40. Behavioural Risk Factor Surveillance System (BRFSS). Influenza and pneumococcal vaccination levels among adults aged > 65 years - United States 1997. Morbidity and Mortality Weekly Report 1998;47(38):797-802.
41. British Thoracic Society. COPD guidelines group of the standards of care committee of the BTS. BTS Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52:S7-15.
42. Collet JP, Shapiro S, Ernst P, Renzi P, Ducruet T, Robinson A, et al. Effects of immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1997;156:1719-24.
43. Galasso GJ, Tyeryar FJ, La Montagne JR. Overview of clinical trials of influenza vaccines 1976. Journal of Infectious Diseases 1977;136(Suppl):S425-8.
44. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf (accessed prior to 9 March 2018).
45. Gorse GJ, O'Connor TZ, Young SL, Habib MP, Wittes J, Neuzil KM, Nichol KL. Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest 2006;130:1109-16.
46. Govaert ME, Dinant GJ, Aretz K, Masurel N, Sprenger MJW, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people:randomised double blind placebo controlled trial. BMJ 1993;307:988-90.
47. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 9 March 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
48. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. Annals of Internal Medicine 1995;123:518-27.
49. Higgins JPT, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
50. Monto AS. Influenza: quantifying morbidity and mortality. American Journal of Medicine 1987;82(Suppl 6A):20-5.
51. Neuzil KM, O'Connor TZ, Gorse GJ, Nichol KL. Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine. Clinical Infectious Diseases 2003;36(2):169-74. 3206870
52. National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. www.nice.org.uk/guidance/cg101 (accessed 5 May 2016).
53. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. New England Journal of Medicine 1994;331:778-84.
54. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, et al. The effectiveness of vaccination against influenza in healthy working adults. New England Journal of Medicine 1995;333:889-93.
55. Nichol KL, Wuorenma J, von Stenberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Archives of Internal Medicine 1998;158:1769-76.
56. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Annals of Internal Medicine 1999;130:397-403.
57. Patriarcha PA. A randomised controlled trial of influenza vaccine in the elderly. JAMA 1994;272(21):1700-1.
58. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
59. Rothbart PH, Kempen BM, Sprenger MJW. Sense and nonsense of influenza vaccination in asthma and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1995;151:1682-6.
60. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. New England Journal of Medicine 2002;347(7):465-71.
61. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). European Respiratory Journal 1995;8:1398-420.
62. Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. Journal of the Medical Association of Thailand 2003;86(6):497-508. 3206876
63. Wongsurakiat P, Maranetra KN, Gulprasutdilog P, Aksornint M, Srilum W, Ruengjam C, et al. Adverse effects associated with influenza vaccination in patients with COPD:a randomized controlled study. Respirology 2004;9:550-6. 3206880
64. Yang IA, Dabscheck EJ, George J, Jenkins SC, McDonald CF, McDonald V, et al. The COPD-X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. copdx.org.au/copd-x-plan/the-copd-x-plan-pdf/ 2017; Vol. (accessed prior to 9 March 2018).
65. Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD002733]
66. Poole P, Chacko EE, Wood-Baker R, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD002733.pub2]